Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Enzyme-catalyzed activation of anticancer prodrugs.

Rooseboom M, Commandeur JN, Vermeulen NP.

Pharmacol Rev. 2004 Mar;56(1):53-102. Review.

2.

Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.

Chen L, Waxman DJ.

Curr Pharm Des. 2002;8(15):1405-16. Review.

PMID:
12052216
3.

Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.

Roy P, Waxman DJ.

Toxicol In Vitro. 2006 Mar;20(2):176-86. Epub 2005 Nov 15. Review.

PMID:
16293390
4.

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.

Wallace PM, Senter PD.

Methods Find Exp Clin Pharmacol. 1994 Sep;16(7):505-12. Review.

PMID:
7885077
5.

Prodrug activation enzymes in cancer gene therapy.

Aghi M, Hochberg F, Breakefield XO.

J Gene Med. 2000 May-Jun;2(3):148-64. Review.

PMID:
10894261
6.

Selective activation of anthracycline prodrugs for use in conjunction with ADEPT.

HariKrishna D, Rao AR, Krishna DR.

Drug News Perspect. 2003 Jun;16(5):309-18. Review.

PMID:
12942162
7.
8.

Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.

Baldwin A, Huang Z, Jounaidi Y, Waxman DJ.

Arch Biochem Biophys. 2003 Jan 1;409(1):197-206.

PMID:
12464259
9.

Development of prodrugs for enzyme-mediated, tumor-selective therapy.

Yoon KJ, Potter PM, Danks MK.

Curr Med Chem Anticancer Agents. 2005 Mar;5(2):107-13. Review.

PMID:
15777218
10.

Prodrugs in cancer chemotherapy.

Connors TA, Knox RJ.

Stem Cells. 1995 Sep;13(5):501-11. Review.

PMID:
8528099
11.

Cytochrome P450-based cancer gene therapy: recent advances and future prospects.

Waxman DJ, Chen L, Hecht JE, Jounaidi Y.

Drug Metab Rev. 1999 May;31(2):503-22. Review.

PMID:
10335450
12.

Enzyme/abzyme prodrug activation systems: potential use in clinical oncology.

Nishi Y.

Curr Pharm Des. 2003;9(26):2113-30. Review.

PMID:
14529409
13.

Tumor-activated prodrugs--a new approach to cancer therapy.

Denny WA.

Cancer Invest. 2004;22(4):604-19. Review.

PMID:
15565818
14.

The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.

Connors TA.

Gene Ther. 1995 Dec;2(10):702-9. Review.

PMID:
8750009
15.

Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?

Nawa A, Tanino T, Luo C, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Nishiyama Y, Kikkawa F.

Anticancer Agents Med Chem. 2008 Feb;8(2):232-9. Review.

PMID:
18288924
16.

Cytochrome P450-based gene therapy for cancer treatment: from concept to the clinic.

Jounaidi Y.

Curr Drug Metab. 2002 Dec;3(6):609-22. Review.

PMID:
12369889
18.

Prodrug strategies in cancer therapy.

Denny WA.

Eur J Med Chem. 2001 Jul-Aug;36(7-8):577-95. Review.

PMID:
11600229
19.

Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy.

Houba PH, Leenders RG, Boven E, Scheeren JW, Pinedo HM, Haisma HJ.

Biochem Pharmacol. 1996 Aug 9;52(3):455-63.

PMID:
8687500
20.

Cytochrome P450-activated prodrugs: targeted drug delivery.

Huttunen KM, Mähönen N, Raunio H, Rautio J.

Curr Med Chem. 2008;15(23):2346-65. Review.

PMID:
18855665
Items per page

Supplemental Content

Write to the Help Desk